Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > We will get company updates in June and August
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(571)
•••
Comment by IrishCanuckon Jun 05, 2021 9:39am
181 Views
Post# 33335759

RE:RE:RE:We will get company updates in June and August

RE:RE:RE:We will get company updates in June and AugustSorry Doccole and Harvey, are you reading something in the emails to be upset about that I'm missing? Legally I think they're watching the wording but they're not saying anything we're not aware of.

NSAIDs take up to six weeks to reach maximum levels in the body, the AME study is six weeks in patients (not a coincidence). Otena has similar pain relief effects as Naproxen at 1/6 the dose, which roughly 150mg daily dose is compared to 500mg twice daily. The study is to de-risk the Phase 3 dose they aim for and they're going to monitor a lot of the parameters they'll be observing in Phase 3. 

Everything seems on track for what they're aiming for as far as I'm seeing. What would Dan or the company come out to say other than the quarterly release and update in August? I'm fired up we're able to get extra data out of the AME study and the Phase 3 study is adaptive, we're going to succeed for sure. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities